Drug delivery are various methodologies used to inject drugs or chemicals into the body. Some of the drug delivery available in the market include, transmucosal, oral, pulmonary, injectable, topical, nasal, implantable, and ocular, among others. Drug delivery comprises of technologies primarily used for the controlled or targeted delivery of various therapeutic agents to treat various diseases or improve the health of the patients. Major factors driving the market growth include the rising incidence of chronic diseases, growing demand for non-invasive drug delivery systems, and increasing R&D expenditures in pharmaceutical companies. Additionally, strategic developments and product launches are likely to emerge as a significant future trend in the market during the forecast period.
Pfizer Inc. and Johnson & Johnson – Notable Market Players in the Drug Delivery Market
The drug delivery market is comprised of top players involving Pfizer Inc, Johnson & Johnson, Becton Dickinson and Co, Novo Nordisk AS, Boston Scientific Corp, Baxter International Inc, Gerresheimer AG, Kindeva Drug Delivery LP, GlaxoSmithKline Plc, Bausch Health Companies, Novartis AG, Sever Pharma Solutions, and Boehringer Ingelheim International. The companies have been implementing various strategies that have helped their growth and, in turn, brought about several breakthroughs and transitions in the industry. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the market players have also deployed several utilized inorganic strategies, including mergers & acquisitions, partnerships, and collaborations.
Below are the major growth strategies undertaken by the players operating in the global drug delivery market:
|
Year |
News |
| Mar-2022 | Pfizer Inc. completed the acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Arena Pharmaceuticals brought to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology. |
| Aug-2022 | Pfizer Inc. and Myovant Sciences announced that the U.S. FDA has approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. Both the companies would jointly commercialize MYFEMBREE in the U.S. |
| Sep-2021 | Baxter International Inc. received the U.S. Food and Drug Administration (FDA) approval and commercial launch of premix Norepinephrine Bitartrate injection (norepinephrine). Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure). |
| Jul-2021 | Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the U.S. launch of Biotrue Hydration Boost Lubricant Eye Drops and Biotrue Micellar Eyelid Cleansing Wipes. Both products are preservative-free and uniquely formulated with naturally inspired ingredients to relieve symptoms associated with irritated, dry eyes. |
| Apr-2021 | Kindeva Drug Delivery LP and Cambridge Healthcare Innovations Limited (CHI) have entered into a collaboration to develop and commercialize CHI’s αeolus dry-powder inhaler (DPI) platform technology. To accelerate platform and product development, Kindeva and CHI evaluate a range of drugs for the αeolus platform. The collaboration leveraged Kindeva’s product development, regulatory affairs, and manufacturing capabilities with CHI’s DPI technology and device development expertise |
